CpG-A TLR9激动剂Vidutolimod联合帕博利珠单抗克服转移性黑色素瘤PD-1阻断耐药
这项Ib期剂量递增研究在44例既往抗PD-1治疗进展或稳定的晚期黑色素瘤患者中,评估瘤内注射Vidutolimod联合静脉帕博利珠单抗的安全性与疗效。联合方案安全性可控,25%患者出现持久缓解,注射与非注射病灶(含内脏)均见肿瘤消退;缓解者基线为无炎症肿瘤,治疗后诱导IFNγ基因签名及系统性CXCL10升高。
要点
- 瘤内Vidutolimod联合帕博利珠单抗在PD-1耐药晚期黑色素瘤中安全性可控。
- 25%患者出现持久缓解,注射与非注射病灶(含内脏)均见消退。
- 缓解者基线为无炎症肿瘤,治疗后诱导IFNγ签名及CXCL10升高。
核心结论
- 瘤内TLR9激动剂Vidutolimod联合帕博利珠单抗安全性可控并显示 promising 临床活性,支持通过诱导IFN反应克服PD-1阻断耐药的进一步开发。
研究设计与样本
- Ib期剂量递增研究,44例既往抗PD-1治疗进展或稳定的晚期黑色素瘤患者接受瘤内递增剂量Vidutolimod联合静脉帕博利珠单抗。
主要发现
- 联合方案安全性可控,25%患者出现持久缓解。
- 注射与非注射病灶(包括内脏病灶)均观察到肿瘤消退。
- 缓解者基线为无炎症肿瘤,治疗后诱导IFNγ基因签名。
- 缓解者治疗后系统性IFN诱导趋化因子CXCL10表达增加。
临床怎么用
- 对于PD-1阻断耐药的晚期黑色素瘤,瘤内Vidutolimod联合帕博利珠单抗可能作为克服耐药的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Patients with advanced melanoma that is resistant to PD-1 blockade therapy have limited treatment options. Vidutolimod (formerly CMP-001), a virus-like particle containing a CpG-A Toll-like receptor 9 (TLR9) agonist, may reverse PD-1 blockade resistance by triggering a strong IFN response to induce and attract antitumor T cells. In the dose-escalation part of this phase Ib study, vidutolimod was administered intratumorally at escalating doses with intravenous pembrolizumab to 44 patients with advanced melanoma who had progressive disease or stable disease on prior anti-PD-1 therapy. The combination of vidutolimod and pembrolizumab had a manageable safety profile, and durable responses were observed in 25% of patients, with tumor regression in both injected and noninjected lesions, including visceral lesions. Patients who responded to vidutolimod and pembrolizumab had noninflamed tumors at baseline and induction of an IFNγ gene signature following treatment, as well as increased systemic expression of the IFN-inducible chemokine CXCL10. SIGNIFICANCE: In this phase Ib study in patients with advanced melanoma, intratumoral TLR9 agonist vidutolimod in combination with pembrolizumab had a manageable safety profile and showed promising clinical activity, supporting the further clinical development of vidutolimod to overcome PD-1 blockade resistance through induction of an IFN response. See related commentary by Sullivan, p. 2960. This article is highlighted in the In This Issue feature, p. 2945.
引用
- Ribas A, Medina T, Kirkwood JM, et al. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021. PMID: 34326162. doi:10.1158/2159-8290.CD-21-0425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。